Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study

Marta Pineda-Moncusí, Sonia Servitja, Ignasi Tusquets, Adolfo Diez-Perez, Albora Rial, Maria Lourdes Cos, Isabel Campodarve, Jaime Rodriguez-Morera, Natalia Garcia-Giralt, Xavier Nogués

Research output: Contribution to journalArticleResearch

3 Citations (Scopus)

Abstract

© 2019, Springer Science+Business Media, LLC, part of Springer Nature. Purpose: The most frequent adverse effects of aromatase inhibitors (AI) are arthralgia and bone loss induction. These reduce the quality of life of patients and their adherence to the treatment. This study evaluates the early AI cessation caused by AI intolerance, and the evolution of joint pain and health-related quality of life (HRQoL) during AI treatment until 1-year after AI completion. Methods: Data of 910 women diagnosed with early breast cancer and candidates for AI were recruited in B-ABLE cohort. AI discontinuation was analyzed by survival analysis, including Kaplan–Meier estimation and Cox regression. Patients were distributed in three groups of the study according to previous tamoxifen (TAM) exposure and length of AI treatment: TAM-2yAI, TAM-3yAI, and 5yAI. Evolution of joint pain and HRQoL in osteoporosis was evaluated using Visual Analog Scale (VAS) and ECOS-16 tests, respectively, from baseline to 1-year after AI completion through repeated-measures ANOVA. Results: Risk of AI discontinuation was increased in patients previously exposed to tamoxifen compared to non-exposed (adjusted HR 5.30 [95% CI 2.23 to 12.57]). VAS and ECOS-16 scores of TAM-2yAI and TAM-3yAI groups increased during AI treatment, mainly during the first 3–12 months. After 1-year from AI completion, values tend to decrease to baseline levels. In 5yAI group, VAS and ECOS-16 levels increased at three months, and VAS remained significantly higher at 1-year post-treatment. Conclusions: AI therapy increased joint pain and reduced HRQoL, mainly during the first year of treatment. Patients previously treated with tamoxifen experienced greater pain when they switched to AI therapy and had an excess risk of discontinuation during the first 12 months. Trial registration: ClinicalTrials.gov: NCT03811509. Registered 28 January 2018-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03811509.
Original languageEnglish
Pages (from-to)53-60
JournalBreast Cancer Research and Treatment
Volume177
DOIs
Publication statusPublished - 30 Aug 2019

Keywords

  • Aromatase inhibitors
  • Arthralgia
  • B-ABLE cohort
  • Breast cancer
  • Health-related quality of life
  • Joint pain
  • Tamoxifen

Fingerprint Dive into the research topics of 'Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study'. Together they form a unique fingerprint.

  • Cite this

    Pineda-Moncusí, M., Servitja, S., Tusquets, I., Diez-Perez, A., Rial, A., Cos, M. L., Campodarve, I., Rodriguez-Morera, J., Garcia-Giralt, N., & Nogués, X. (2019). Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study. Breast Cancer Research and Treatment, 177, 53-60. https://doi.org/10.1007/s10549-019-05289-7